Business
Noxopharm (ASX:NOX) share price closes 21% higher after clinical milestone // The Motley Fool Australia
The Noxopharm Ltd (ASX: NOX) share price gained more than 21% today, surging in a last-minute buying frenzy to close at 83 cents.
Noxopharm is an Australian clinical-stage drug development company. Its Veyonda drug is being designed to support cancer patients undertaking chemotherapy or radiotherapy treatment.
Noxopharm share price rockets upon survival benefit results
The company announced today that it would present its latest research findings at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium later this week.
The research pertains to extending the lives of patients who have late-stage prostate cancer.
Noxopharm’s LuPIN study enrolled a total of 56 patients with metastatic…
-
Noosa News21 hours agoLaidley e-scooter death: Tragic new details after Summah Richards killed in freak accident
-
General22 hours agoMinjee Lee rallies after third-round meltdown to share fifth place at LA Championship
-
General15 hours agoUkraine says Russia has ramped up attacks despite ‘Easter truce’
-
General14 hours agoPope Francis appears Easter Sunday to deliver blessing as recovery continues